After close to a decade of late-stage studies and stinging setbacks, The Medicines Co. may finally be on the verge of seeing its blood-thinner cangrelor make it to the market. But the late comeback may be far too little and too late to do much good as sales of its franchise therapy Angiomax drop ahead of what is expected to be brutal generic competition later this year.

…read more

Source: After PhIII odyssey, the FDA finally gives Medicines Co. a thumbs-up for cangrelor


0 No comments